September 25, 2013

Response Genetics, Inc. Announces Contract With Three Rivers Provider Network

LOS ANGELES, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has entered into an agreement with Three Rivers Provider Network, one of the country's largest and fastest-growing proprietary PPO networks.

Three Rivers Provider Network offers healthcare benefits to over 10 million members located throughout the United States through its supplemental PPO Network Foundation.  These members will now have access to Response Genetics' portfolio of predictive genomic testing.  Response Genetics' specialization focuses on the linkage between the genetic profile of an individual cancer patient's tumor and various drugs that may be used to fight that cancer.  This partnership between the two companies will offer Three Rivers Provider Network and its clients enhanced access to precision medicine.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

About Three Rivers Provider Network

Three Rivers Provider Network has evolved into the largest and fastest-growing proprietary PPO network in the U.S.  The TRPN network is comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities.  Through its clients, more than 10 million people have access to the TRPN PPO network.  For more information please visit www.trpnppo.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Investor Relations Contact:

         Peter Rahmer

         Trout Group

         646-378-2973



         Company Contact:

         Thomas A. Bologna

         Chairman & Chief Executive Officer

         323-224-3900

Response Genetics Logo

Source: Response Genetics, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 Response Genetics, Inc.